来源：科技日报 ◎ 科技日报记者 张佳星 神经退行性疾病的脑网络病变机制当前尚不明确，致使针对脑功能异常的治疗如"盲人摸象"，进展缓 慢。2月5日，《自然》杂志发表的一项成果首次清晰揭示了帕金森病的致病关键环路，针对该环路进行 精准靶向的磁刺激可以有效改善患者的症状，证明了该机制的重要临床意义。 "我们发现大脑的一个关键脑网络在帕金森病中发挥核心作用，这个网络是由大脑皮层功能区和脑深部 核团共同构成的大规模网络，我们称它为躯体认知环路。"论文通讯作者、昌平实验室领衔科学家刘河 生教授说，与健康人群相比，帕金森病患者的躯体认知环路表现出显著的过度连接。 团队发现，躯体认知环路的过度连接在多个帕金森病患者的独立数据集中均得到了重复验证，但并未出 现在肌张力障碍等其他疾病中。深度分析显示，现有有效治疗帕金森病的手段都是通过改善躯体认知环 路发挥作用，如深部脑刺激手术中的"有效刺激位点"区域与该关键网络相关。更强有力的证据在于，团 队在运动症状改善的患者大脑内观察到过度连接的下降，表明深部脑刺激是通过特异性下调这一环路的 异常连接而发挥治疗作用。 "我们的发现为靶向干预提供了精准'靶点'。"刘河生介绍，基于此发现，团 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 帕金森病 （PD） 是一种无法治愈的神经退行性疾病，通常以隐匿的睡眠障碍和躯体症状开始，逐渐发展 为全身性运动和认知症状。 躯体-认知-行动网络 （ somato-cognitive action network， SCAN ） 的功 能障碍——该网络被认为通过协调觉醒状态、器官生理机能、全身运动计划与行为动机来控制动作执行 ——可能是导致帕金森病多样化临床表现的重要因素。 因此， 针对 SCAN 的特定神经调控，可能有助于治疗并改善帕金森病的症状。 2026 年 2 月 4 日，昌平实验室/北京大学 刘河生 教授 、 任建勋 、 王聃红 及 河南省人民医院 王梅云 教授作为共同通讯作者（ 任建勋 、 张维 为论文共同第一作者 ），在国际顶尖学术期刊 Nature 上发表了 题为： Parkinson's disease as a somato-cognitive action network disorder 的研究论文。 该研究 首次在功能环路层面揭示了帕金森病的关键异常机制 ，揭示了帕金森病是一种 躯体-认知-行动网 络障碍 （ somato-cognitive ...

oi e D 0 0 流溪 03 野盟 館 新 首都 蘭館 遊戲 老年PD患者吞咽障碍长期存在会导致患者误吸、吸入性肺炎、营养不良、脱水、心理与社会交往障 碍、窒息甚至死亡等问题，直接影响疾病预后，严重威胁患者生命健康与安全。 日常建议及注意事项 l 膠毛弓. a finish in the state of the state of the state of the station of the state of the sta ... a~ y Restar 9 2 CS 2 2 M T # 1 V 民以食为天，进食能使人倍感幸福，无法享受美食则会感到焦虑和沮丧。 帕金森病的定义 帕金森病（Parkinson' s disease，PD）是一种常见的与年龄密切相关的中枢神经系统退行性疾病。静止 性震颤、运动迟缓、肌强直和姿势步态异常等为常见运动症状。 吞咽障碍是PD患者常见的非运动症状，可发生在病程的任何阶段，起病隐匿常易被忽略，其发病率为 35%-82%，在我国65 岁以上人群患病率约为 2%。 P ( de l 1 J l 老年PD患者病情多样且复杂，患者需遵医嘱坚持服用左旋多巴药物治疗。同时主张多学 ...

半年前,李大爷开始出现走路拖沓、双脚间距变宽,家属最初以为是腰椎问题或衰老的自然表现,但病情进 展远超预期。短短三个月内,他步态不稳、频繁摔倒,记忆力衰退、反应迟钝,甚至出现尿失禁,生活完全依 赖家人照料。 为找出病因,他辗转三家医院,先后就诊于骨科、泌尿外科、老年病科,腰椎CT、前列腺彩超等检查结果 正常,初步诊断倾向"老年痴呆"。然而,按老年痴呆方案治疗一段时间后,症状非但未改善,反而持续恶化。 在局部麻醉下,张伟伟主任通过腰椎穿刺术为李大爷释放40ml脑脊液。放液后两小时,李大爷在搀扶下平 稳行走,步速加快,认知反应更敏捷,尿失禁也暂时缓解。"正常颅压脑积水是少有的可治性痴呆相关疾 病。"张伟伟主任呼吁,老年人出现"步态不稳、认知减退、尿失禁"三联征时,应及时到神经内科就诊,通 过头颅CT/MRI、脑脊液检查明确诊断,避免被老年痴呆、帕金森等常见病掩盖。 直至近日,荣成市人民医院神经内二科团队抽丝剥茧,才揭开这场被常见老年病"掩盖"的真相——特发性 正常颅压脑积水(iNPH)。神经内二科张伟伟主任指出,阿尔茨海默病早期通常无步态障碍,帕金森病则多 伴震颤和单侧症状,而李大爷的症状进展快,与老年退行性疾病 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 溶酶体 （ Lysosome ） 维持着高度酸化 （pH=4.5-5.0） 的内部环境，以调控 H + 依赖的水解酶介导的 降解作用。 此外， 溶酶体的酸性 pH 还能在细胞质一侧调控多种细胞器功能， 这也意味着必须存在一种 从 溶酶体内部到细胞质的机制将内部的酸度信息传递给 细胞质中的效应因子。然而， H + （即质子） 如 何从 溶酶体 中"泄漏"出来以调控细胞质中的细胞器功能，目前仍不清楚。 2026 年 1 月 26 日，中国科学院杭州医学研究所/湖南大学 谭蔚泓 院士 、湖南大学 邱丽萍 教授、浙江 大学 徐浩新 教授等，在 Nature 子刊 Nature Cell Biology 上发表了题为： DNA nanodevices detect an acidic nanolayer on the lysosomal surface 的研究论文。 该研究利用创新的 DNA 纳米设备 （ DNA Nanodevice，DN ） ，首次 在活细胞中直接观测到 溶酶体 表 面存在一个至多 21 纳米厚的 酸性纳米层 。这一发现表明， 溶酶体 就像一座城堡，不仅内部是 ...

Core Viewpoint - The film "Ma Teng, Don't Go" features actor Li Youbin, who portrays a retired worker suffering from Parkinson's disease and depression, marking a significant departure from his previous roles and showcasing the emotional depth of the character [3][5]. Group 1: Character and Story Development - The film tells the story of Lao Lin, a retired steel factory worker, who forms a deep bond with a carefree individual named Ma Teng, highlighting themes of companionship and resilience in the face of adversity [3][4]. - Li Youbin emphasized the importance of understanding the character's psychological struggles, particularly the nuances of Lao Lin's thoughts on life and death, which are central to the narrative [5][6]. Group 2: Actor's Preparation and Challenges - Li Youbin undertook extensive research on Parkinson's disease and depression to authentically portray Lao Lin, recognizing the character's complex emotional landscape [5][6]. - This role represents Li Youbin's first foray into comedy, where he discovered humor within the script, aiming for a natural and authentic comedic performance [6]. Group 3: Emotional Dynamics - The relationship between Lao Lin and Ma Teng evolves from initial misunderstandings to a profound emotional connection, resembling a father-son dynamic, which ultimately influences Lao Lin's decision to embrace life [4][5]. - Li Youbin noted that the companionship with Ma Teng provided Lao Lin with a sense of purpose and joy, contrasting with his previous feelings of isolation [4][5].

Core Viewpoint - The film "Ma Teng, Don't Leave" features actor Li Youbin, who portrays a retired worker suffering from Parkinson's disease and depression, marking a significant departure from his previous roles and showcasing the emotional depth of the character [1][3]. Group 1: Character and Role Preparation - Li Youbin took time to understand the character of Lao Lin, a retired steelworker, by reading the script multiple times and engaging in discussions with the director, which helped him connect emotionally with the role [3][4]. - The character Lao Lin embodies traits such as integrity, honesty, and a strong sense of self-respect, which are challenged by his health issues and feelings of isolation [3][4]. - Li Youbin researched Parkinson's disease and depression to accurately portray the struggles faced by his character, emphasizing the reality of Lao Lin's suicidal thoughts as a genuine response to his circumstances [4][5]. Group 2: Relationship Dynamics - The film explores the evolving relationship between Lao Lin and Ma Teng, highlighting themes of companionship and emotional support as they navigate their challenges together [3][4]. - Li Youbin noted that the bond formed between Lao Lin and Ma Teng transcends typical familial relationships, suggesting a deeper emotional connection akin to a father-son dynamic [4][5]. Group 3: Performance Style and Challenges - This film marks Li Youbin's first attempt at incorporating comedic elements into his performance, adapting to the film's unique style while maintaining a realistic approach [4][5]. - The actor experienced new challenges, such as performing stunts with a wheelchair, which added a layer of excitement and complexity to his role [4].

Core Insights - Parkinson's disease is often misunderstood as merely causing "tremors," but its symptoms are complex and vary significantly among individuals, leading to potential misdiagnosis [1][2] Symptom Summary - Tremors are the most common initial symptom, typically starting in one hand and characterized by involuntary shaking that is more pronounced at rest and diminishes with movement [1] - Muscle rigidity manifests as a feeling of tightness or stiffness during movement, making daily activities challenging and reducing facial expressions [1] - Bradykinesia, or slowed movement, affects daily tasks, making them cumbersome and leading to difficulties in starting and stopping walking, as well as writing [1] - Balance issues arise in the mid to late stages of the disease, increasing the risk of falls, particularly during turns or on uneven surfaces [2] Diagnostic Indicators - The combination of "slow + tremor" or "slow + rigidity" should raise high suspicion for Parkinson's disease [2] - The characteristic of "slow" typically indicates unilateral onset, with gradual progression to the opposite side, while bilateral symptoms may suggest natural aging or other conditions [3] Self-Assessment Method - The "nail board test" can be used for self-assessment, where individuals over 60 should be able to insert at least 17 nails per hand in one minute; lower scores warrant further investigation [4]

Core Viewpoint - The prevalence of Parkinson's disease is increasing, closely linked to population aging and the rise of neurodegenerative diseases like Alzheimer's and Parkinson's [1][3]. Group 1: Understanding Parkinson's Disease - The understanding of Parkinson's disease has evolved significantly over the past 31 years, particularly with the introduction of PET imaging agents that allow for the visualization of dopamine transporters in the brain [3][4]. - The core issue in Parkinson's disease is the loss of dopamine neurons, which leads to symptoms such as tremors, slowness, and stiffness [3][15]. - Tremors are commonly associated with Parkinson's disease, but not all patients exhibit this symptom; slowness is considered the most critical feature for diagnosis [6][8]. Group 2: Diagnosis and Symptoms - Objective tests, particularly PET imaging, are emphasized for accurate diagnosis, as Parkinson's disease symptoms can be subtle and difficult to assess [4][5]. - Key symptoms include slowness, stiffness, and tremors, with slowness being a necessary condition for diagnosis [7][8]. - Distinguishing between age-related slowness and slowness due to Parkinson's is crucial, as they present differently [10][13]. Group 3: Treatment Options - Standard treatment primarily involves medication, particularly dopamine precursors like levodopa, which can improve symptoms significantly [18][19]. - Long-term use of medication may lead to diminished effectiveness, but it is essential for maintaining quality of life [20][22]. - Surgical options, such as Deep Brain Stimulation (DBS), are available for patients who do not respond adequately to medication [23][24]. Group 4: Research and Future Directions - Research is ongoing into the role of alpha-synuclein protein aggregation in Parkinson's disease, with new imaging agents being developed to monitor this process [15][17]. - There is potential for stem cell therapy, but it remains in the clinical trial phase and requires careful evaluation [27][28]. - Preventive measures include lifestyle changes such as exercise and dietary adjustments, which may help reduce the risk of developing Parkinson's disease [32].

Summary of the Conference Call on Maiwei Biotech and the Tracer Project Company and Industry Overview - **Company**: Maiwei Biotech - **Industry**: Neurodegenerative Diseases, specifically focusing on Parkinson's Disease (PD) and Multiple System Atrophy (MSA) through the Tracer project [2][4] Key Points and Arguments 1. **Tracer Project Overview**: - Tracer is a novel radiolabeled small molecule drug targeting PD and MSA, with significant application potential and a clear clinical development path [2][4] - It is the only team globally developing such a tracer for PD, aiming to be the first approved tracer for this condition [2][4] 2. **Funding and Support**: - The project has received unconditional funding from the MicroG Fox Foundation, indicating strong scientific and commercial backing [2][5] - Collaboration with top research institutions, including the Chinese Academy of Sciences, enhances the project's credibility and potential [2][6] 3. **Clinical Development Timeline**: - FDA IND approval is expected in 2025, with the first patient enrollment planned for Q4 2025 [5][6] - The Chinese IND is anticipated to be approved in early 2026, with over 100 patient imaging studies already conducted at Huashan Hospital [5][6] 4. **Market Potential**: - The Tracer project targets a large unmet market for PD, with no similar products currently approved, positioning Maiwei Biotech to set new treatment standards [6][10] - The project is expected to solidify Maiwei's position in the chronic disease sector, particularly in age-related diseases [6][10] 5. **Operational Model**: - Maiwei is the largest external investor in the project, which operates independently but leverages Maiwei's core operational capabilities [3][8] - The company plans to explore overseas licensing and transfer opportunities as the project matures [9][20] 6. **Clinical Trial Design**: - Phase I trials will focus on safety, radiation dosimetry, and pharmacokinetics, with a target enrollment of 20 to 30 patients [15][22] - The project faces challenges in obtaining post-mortem data for validation, which may require international collaboration [15][22] 7. **Challenges in Commercialization**: - High costs and lack of insurance coverage for PD diagnostics may hinder market acceptance [15][18] - The company plans to integrate diagnostic tools with therapeutic drugs to enhance market uptake [15][18] 8. **AI Integration**: - AI technology is being explored to improve imaging analysis and diagnostic accuracy, potentially increasing market penetration [16][18] 9. **Future Development Plans**: - Maiwei is committed to expanding its pipeline in neurodegenerative diseases, including Alzheimer's, while adopting differentiated strategies to enhance drug development efficiency [14][24] 10. **Shareholding Structure**: - Maiwei holds a 35% stake in the Tracer project, with plans to potentially increase investment to meet clinical needs and achieve commercialization [23][24] Additional Important Insights - The Tracer project is positioned as a first-in-class solution in the PD space, with significant implications for future investment returns compared to the Alzheimer's market, which has multiple approved tracers [10][12] - The collaboration with international partners and the establishment of a robust BD network are crucial for the project's success and future opportunities [11][19]